Amending Synthetic Drug Control Act Exposed

From ALEC Exposed
Jump to: navigation, search
Model Bill Info
Bill Title Amending Synthetic Drug Control Act
Date Introduced July 29, 2016
Date Finalized September 12, 2016
Date Accessed April 27, 2018
Type Model Policy
Status Final
Task Forces Health and Human Services
Keywords Drugs


Summary

Amends ineffective law that simply address the problem of synthetic drugs by passing legislation to make specific chemical formulations of synthetic drugs illegal. These specific chemical formulations become dated quickly. This bill goes after broad base formulations that create or mimic the effect of cannabis or certain controlled substances and thereby helps law enforcement to stay ahead of criminal drug activity. Additionally it addresses weakness in the Analog statute that allows clever distributors to cloak products with an innocuous name in order to insulate themselves by marking packages: “Not For Human Consumption.”

Amending Synthetic Drug Control Act

Section 1. Short Title. Amending Synthetic Drug Control

Section 2. Purpose. Adds various synthetic drug compounds including various structural classes of those compounds to the list of Schedule I controlled substances. Deletes from the definition of controlled substance analog the requirement that a substance must be intended for human consumption to be considered an analog of a controlled substance with a chemical structure substantially similar to that of a controlled substance in Schedule I or II, or that was specifically designed to produce an effect substantially similar to that of a controlled substance in Schedule I or II.

Section 3. Definition.

(f) “Controlled Substance” means (i) a drug, substance, or

immediate precursor, or synthetic drug in the Schedules of

Article II of this Act or (ii) a drug or other substance, or

immediate precursor, designated as a controlled substance by

the Department through administrative rule. The term does not

include distilled spirits, wine, malt beverages, or tobacco, as terms are defined or used in… (Reference local state definitions of terms)

Section 4. Amending Synthetic Drug Control Act.

Sec. 204.

(a) The controlled substances listed in this

Section are included in Schedule I.

(b) Unless specifically excepted or unless listed in

another schedule, any of the following opiates, including their

isomers, esters, ethers, salts, and salts of isomers, esters,

and ethers, whenever the existence of such isomers, esters,

ethers and salts is possible within the specific chemical

designation:

(1) Acetylmethadol;

(1.1) Acetyl-alpha-methylfentanyl

(N-[1-(1-methyl-2-phenethyl)-

4-piperidinyl]-N-phenylacetamide);

(2) Allylprodine;

(3) Alphacetylmethadol, except

levo-alphacetylmethadol (also known as levo-alpha-

acetylmethadol, levomethadyl acetate, or LAAM);

(4) Alphameprodine;

(5) Alphamethadol;

(6) Alpha-methylfentanyl

(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-

propanilido) piperidine;

(6.1) Alpha-methylthiofentanyl

(N-[1-methyl-2-(2-thienyl)ethyl-

4-piperidinyl]-N-phenylpropanamide);

(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);

(7.1) PEPAP

(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);

(8) Benzethidine;

(9) Betacetylmethadol;

(9.1) Beta-hydroxyfentanyl

(N-[1-(2-hydroxy-2-phenethyl)-

4-piperidinyl]-N-phenylpropanamide);

(10) Betameprodine;

(11) Betamethadol;

(12) Betaprodine;

(13) Clonitazene;

(14) Dextromoramide;

(15) Diampromide;

(16) Diethylthiambutene;

(17) Difenoxin;

(18) Dimenoxadol;

(19) Dimepheptanol;

(20) Dimethylthiambutene;

(21) Dioxaphetylbutyrate;

(22) Dipipanone;

(23) Ethylmethylthiambutene;

(24) Etonitazene;

(25) Etoxeridine;

(26) Furethidine;

(27) Hydroxpethidine;

(28) Ketobemidone;

(29) Levomoramide;

(30) Levophenacylmorphan;

(31) 3-Methylfentanyl

(N-[3-methyl-1-(2-phenylethyl)-

4-piperidyl]-N-phenylpropanamide);

(31.1) 3-Methylthiofentanyl

(N-[(3-methyl-1-(2-thienyl)ethyl-

4-piperidinyl]-N-phenylpropanamide);

(32) Morpheridine;

(33) Noracymethadol;

(34) Norlevorphanol;

(35) Normethadone;

(36) Norpipanone;

(36.1) Para-fluorofentanyl

(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-

4-piperidinyl]propanamide);

(37) Phenadoxone;

(38) Phenampromide;

(39) Phenomorphan;

(40) Phenoperidine;

(41) Piritramide;

(42) Proheptazine;

(43) Properidine;

(44) Propiram;

(45) Racemoramide;

(45.1) Thiofentanyl

(N-phenyl-N-[1-(2-thienyl)ethyl-

4-piperidinyl]-propanamide);

(46) Tilidine;

(47) Trimeperidine;

(48) Beta-hydroxy-3-methylfentanyl (other name:

N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-

N-phenylpropanamide).

(c) Unless specifically excepted or unless listed in

another schedule, any of the following opium derivatives, its

salts, isomers and salts of isomers, whenever the existence of

such salts, isomers and salts of isomers is possible within the

specific chemical designation:

(1) Acetorphine;

(2) Acetyldihydrocodeine;

(3) Benzylmorphine;

(4) Codeine methylbromide;

(5) Codeine-N-Oxide;

(6) Cyprenorphine;

(7) Desomorphine;

(8) Diacetyldihydromorphine (Dihydroheroin);

(9) Dihydromorphine;

(10) Drotebanol;

(11) Etorphine (except hydrochloride salt);

(12) Heroin;

(13) Hydromorphinol;

(14) Methyldesorphine;

(15) Methyldihydromorphine;

(16) Morphine methylbromide;

(17) Morphine methylsulfonate;

(18) Morphine-N-Oxide;

(19) Myrophine;

(20) Nicocodeine;

(21) Nicomorphine;

(22) Normorphine;

(23) Pholcodine;

(24) Thebacon.

(d) Unless specifically excepted or unless listed in

another schedule, any material, compound, mixture, or

preparation which contains any quantity of the following

hallucinogenic substances, or which contains any of its salts,

isomers and salts of isomers, whenever the existence of such

salts, isomers, and salts of isomers is possible within the

specific chemical designation (for the purposes of this

paragraph only, the term “isomer” includes the optical,

position and geometric isomers):

(1) 3,4-methylenedioxyamphetamine

(alpha-methyl,3,4-methylenedioxyphenethylamine,

methylenedioxyamphetamine, MDA);

(1.1) Alpha-ethyltryptamine

(some trade or other names: etryptamine;

MONASE; alpha-ethyl-1H-indole-3-ethanamine;

3-(2-aminobutyl)indole; a-ET; and AET);

(2) 3,4-methylenedioxymethamphetamine (MDMA);

(2.1) 3,4-methylenedioxy-N-ethylamphetamine

(also known as: N-ethyl-alpha-methyl-

3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

and MDEA);

(2.2) N-Benzylpiperazine (BZP);

(2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

(4) 3,4,5-trimethoxyamphetamine (TMA);

(5) (Blank);

(6) Diethyltryptamine (DET);

(7) Dimethyltryptamine (DMT);

(7.1) 5-Methoxy-diallyltryptamine;

(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

(9) Ibogaine (some trade and other names:

7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

6,9-methano-5H-pyrido [1′,2′:1,2] azepino [5,4-b]

indole; Tabernanthe iboga);

(10) Lysergic acid diethylamide;

(10.1) Salvinorin A;

(10.5) Salvia divinorum (meaning all parts of the plant

presently classified botanically as Salvia divinorum,

whether growing or not, the seeds thereof, any extract from

any part of that plant, and every compound, manufacture,

salts, isomers, and salts of isomers whenever the existence

of such salts, isomers, and salts of isomers is possible

within the specific chemical designation, derivative,

mixture, or preparation of that plant, its seeds or

extracts);

(11) 3,4,5-trimethoxyphenethylamine (Mescaline);

(12) Peyote (meaning all parts of the plant presently

classified botanically as Lophophora williamsii Lemaire,

whether growing or not, the seeds thereof, any extract from

any part of that plant, and every compound, manufacture,

salts, derivative, mixture, or preparation of that plant,

its seeds or extracts);

(13) N-ethyl-3-piperidyl benzilate (JB 318);

(14) N-methyl-3-piperidyl benzilate;

(14.1) N-hydroxy-3,4-methylenedioxyamphetamine

(also known as N-hydroxy-alpha-methyl-

3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

(15) Parahexyl; some trade or other names:

3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

dibenzo (b,d) pyran; Synhexyl;

(16) Psilocybin;

(17) Psilocyn;

(18) Alpha-methyltryptamine (AMT);

(19) 2,5-dimethoxyamphetamine

(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

(20) 4-bromo-2,5-dimethoxyamphetamine

(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

4-bromo-2,5-DMA);

(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

Some trade or other names: 2-(4-bromo-

2,5-dimethoxyphenyl)-1-aminoethane;

alpha-desmethyl DOB, 2CB, Nexus;

(21) 4-methoxyamphetamine

(4-methoxy-alpha-methylphenethylamine;

paramethoxyamphetamine; PMA);

(22) (Blank);

(23) Ethylamine analog of phencyclidine.

Some trade or other names:

N-ethyl-1-phenylcyclohexylamine,

(1-phenylcyclohexyl) ethylamine,

N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

(24) Pyrrolidine analog of phencyclidine. Some trade

or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

PHP;

(25) 5-methoxy-3,4-methylenedioxy-amphetamine;

(26) 2,5-dimethoxy-4-ethylamphetamine

(another name: DOET);

(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

(another name: TCPy);

(28) (Blank);

(29) Thiophene analog of phencyclidine (some trade

or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

2-thienyl analog of phencyclidine; TPCP; TCP);

(30) Bufotenine (some trade or other names:

3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

3-(2-dimethylaminoethyl)-5-indolol;

5-hydroxy-N,N-dimethyltryptamine;

N,N-dimethylserotonin; mappine);

(31) 1-Pentyl-3-(1-naphthoyl)indole

Some trade or other names: JWH-018;

(32) 1-Butyl-3-(1-naphthoyl)indole

Some trade or other names: JWH-073;

(33) 1-[(5-fluoropentyl)-1H-indol-3-yl]-

(2-iodophenyl)methanone

Some trade or other names: AM-694;

(34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-

(2-methyloctan-2-yl)phenol

Some trade or other names: CP 47,497

and its C6, C8 and C9 homologs;

(34.5) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-

(2-methyloctan-2-yl)phenol), where side chain n=5;

and homologues where side chain n=4, 6, or 7; Some

trade or other names: CP 47,497;

(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

(2-methyloctan-2-yl)-6a,7,

10,10a-tetrahydrobenzo[c]chromen-1-ol

Some trade or other names: HU-210;

(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-

dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-

tetrahydrobenzo[c]chromen-1-ol, its isomers,

salts, and salts of isomers; Some trade or other

names: HU-210, Dexanabinol;

(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-

6,6-dimethyl-3-(2-methyloctan-2-yl)-

6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

Some trade or other names: HU-211;

(37) (2-methyl-1-propyl-1H-indol-

3-yl)-1-naphthalenyl-methanone

Some trade or other names: JWH-015;

(38) 4-methoxynaphthalen-1-yl-

(1-pentylindol-3-yl)methanone

Some trade or other names: JWH-081;

(39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole

Some trade or other names: JWH-122;

(40) 2-(2-methylphenyl)-1-(1-pentyl-

1H-indol-3-yl)-ethanone

Some trade or other names: JWH-251;

(41) 1-(2-cyclohexylethyl)-3-

(2-methoxyphenylacetyl)indole

Some trade or other names: RCS-8, BTW-8 and SR-18;

(42) Any compound structurally derived from

3-(1-naphthoyl)indole or 1H-indol-3-yl-

(1-naphthyl)methane by substitution at the

nitrogen atom of the indole ring by alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,

or 2-(4-morpholinyl)ethyl whether or not further

substituted in the indole ring to any extent, whether

or not substituted in the naphthyl ring to any extent.

Examples of this structural class include, but are

not limited to, JWH-018, AM-2201, JWH-175, JWH-184,

and JWH-185;

(43) Any compound structurally derived from

3-(1-naphthoyl)pyrrole by substitution at the nitrogen

atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl

aryl halide, 1-(N-methyl-2-piperidinyl)methyl,

or 2-(4-morpholinyl)ethyl, whether or not further

substituted in the pyrrole ring to any extent, whether

or not substituted in the naphthyl ring to any extent.

Examples of this structural class include, but are not

limited to, JWH-030, JWH-145, JWH-146, JWH-307, and

JWH-368;

(44) Any compound structurally derived from

1-(1-naphthylmethyl)indene by substitution

at the 3-position of the indene ring by alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl

halide, alkyl aryl halide, 1-(N-methyl-

2-piperidinyl)methyl, or 2-(4-

morpholinyl)ethyl whether or not further substituted in

the indene ring to any extent, whether or not substituted

in the naphthyl ring to any extent. Examples of

this structural class include, but are not

limited to, JWH-176;

(45) Any compound structurally derived from

3-phenylacetylindole by substitution at the

nitrogen atom of the indole ring with alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl

halide, alkyl aryl halide, 1-(N-methyl-2-

piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

whether or not further substituted in the indole ring

to any extent, whether or not substituted in the phenyl

ring to any extent. Examples of this structural

class include, but are not limited to, JWH-167,

JWH-250, JWH-251, and RCS-8;

(46) Any compound structurally derived from

2-(3-hydroxycyclohexyl)phenol by substitution

at the 5-position of the phenolic ring by alkyl,

haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

aryl halide, alkyl aryl halide, 1-(N-methyl-2-

piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

whether or not substituted in the cyclohexyl ring to any

extent. Examples of this structural class

include, but are not limited to, CP 47,

497 and its C8 homologue (cannabicyclohexanol);

(46.1) Benzoylindoles: Any compound

containing a 3-(benzoyl) indole structure with

substitution at the nitrogen atom of the

indole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl,

1-(N-methyl-2-piperidinyl)methyl,

or 2-(4-morpholinyl)ethyl group

whether or not further substituted

in the indole ring to any extent and

whether or not substituted in the phenyl ring

to any extent. Examples of this structural class

include, but are not limited, to AM-630,

AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;

(47) 3,4-Methylenedioxymethcathinone

Some trade or other names: Methylone;

(48) 3,4-Methyenedioxypyrovalerone

Some trade or other names: MDPV;

(49) 4-Methylmethcathinone

Some trade or other names: Mephedrone;

(50) 4-methoxymethcathinone;

(51) 4-Fluoromethcathinone;

(52) 3-Fluoromethcathinone;

(53) 2,5-Dimethoxy-4-(n)-propylthio-

phenethylamine;

(54) 5-Methoxy-N,N-diisopropyltryptamine;

(55) Pentedrone;

(56) 4-iodo-2,5-dimethoxy-N-((2-methoxy

phenyl)methyl)-benzeneethanamine

(trade or other name: 25I-NBOMe);

(57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)

methyl]-benzeneethanamine (trade or other name:

25C-NBOMe);

(58) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)

methyl]-benzeneethanamine (trade or other name:

25B-NBOMe); .

(59) 3-cyclopropoylindole with

substitution at the nitrogen atom of the

indole ring by alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, aryl

halide, alkyl aryl halide,

1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not

further substituted on the indole ring

to any extent, whether or not substituted

on the cyclopropyl ring to any extent:

including but not limited to XLR11,

UR144, FUB-144;

(60) 3-adamantoylindole with

substitution at the nitrogen atom of the

indole ring by alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl,

aryl halide, alkyl aryl halide,

1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not

further substituted on the indole ring to

any extent, whether or not substituted on

the adamantyl ring to any extent: including

but not limited to AB-001;

(61) N-(adamantyl)-indole-3-carboxamide

with substitution at the nitrogen atom of the

indole ring by alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, aryl halide,

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,

or 2-(4-morpholinyl)ethyl, whether or not further

substituted on the indole ring to any extent, whether

or not substituted on the adamantyl ring to any

extent: including but not limited to

APICA/2NE-1, STS-135;

(62) N-(adamantyl)-indazole-3-carboxamide

with substitution at a nitrogen atom of the indazole

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

cycloalkylethyl, aryl halide, alkyl aryl halide,

1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not further

substituted on the indazole ring to any extent,

whether or not substituted on the adamantyl

ring to any extent: including but not limited

to AKB48, 5F-AKB48;

(63) 1H-indole-3-carboxylic acid 8-quinolinyl

ester with substitution at the nitrogen atom of the

indole ring by alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not further

substituted on the indole ring to any extent,

whether or not substituted on the quinoline ring

to any extent: including but not limited to PB22,

5F-PB22, FUB-PB-22;

(64) 3-(1-naphthoyl)indazole with

substitution at the nitrogen atom of the

indazole ring by alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl,

aryl halide, alkyl aryl halide,

1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not further

substituted on the indazole ring to any extent,

whether or not substituted on the naphthyl ring

to any extent: including but not limited to

THJ-018, THJ-2201;

(65) 2-(1-naphthoyl)benzimidazole with

substitution at the nitrogen atom of the benzimidazole

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

cycloalkylethyl, aryl halide, alkyl aryl halide,

1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not further

substituted on the benzimidazole ring to any extent,

whether or not substituted on the naphthyl ring to

any extent: including, but not limited to FUBIMINA;

(66) N-(1-amino-3-methyl-1-oxobutan-2-yl)

-1H-indazole-3-carboxamide with substitution on the

nitrogen atom of the indazole ring by alkyl,

haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

aryl halide, alkyl aryl halide, 1-(N-methyl-2-

piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

whether or not further substituted on the indazole

ring to any extent: including but not limited to

AB-PINACA, AB-FUBINACA, AB-CHMINACA;

(67) N-(1-amino-3,3-dimethyl-1-oxobutan-

2-yl)-1H-indazole-3-carboxamide with substitution

on the nitrogen atom of the indazole ring by alkyl,

haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

aryl halide, alkyl aryl halide, 1-(N-methyl-2-

piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether

or not further substituted on the indazole ring to any

extent: including but not limited to ADB-PINACA,

ADB-FUBINACA;

(68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-

1H-indole-3-carboxamide with substitution on the nitrogen

atom of the indole ring by alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not further

substituted on the indole ring to any extent:

including but not limited to ADBICA, 5F-ADBICA;

(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-

1H-indole-3-carboxamide with substitution on the

nitrogen atom of the indole ring by alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl

halide, alkyl aryl halide, 1-(N-methyl-2-

piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

whether or not further substituted on the indole

ring to any extent: including but not limited

to ABICA, 5F-ABICA;

(70) Methyl 2-(1H-indazole-3-carboxamido)-

3-methylbutanoate with substitution on the nitrogen

atom of the indazole ring by alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl

halide, alkyl aryl halide, 1-(N-methyl-2-

piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

whether or not further substituted on the indazole

ring to any extent: including but not limited to AMB,

5F-AMB.

(e) Unless specifically excepted or unless listed in

another schedule, any material, compound, mixture, or

preparation which contains any quantity of the following

substances having a depressant effect on the central nervous

system, including its salts, isomers, and salts of isomers

whenever the existence of such salts, isomers, and salts of

isomers is possible within the specific chemical designation:

(1) mecloqualone;

(2) methaqualone; and

(3) gamma hydroxybutyric acid.

(f) Unless specifically excepted or unless listed in

another schedule, any material, compound, mixture, or

preparation which contains any quantity of the following

substances having a stimulant effect on the central nervous

system, including its salts, isomers, and salts of isomers:

(1) Fenethylline;

(2) N-ethylamphetamine;

(3) Aminorex (some other names:

2-amino-5-phenyl-2-oxazoline; aminoxaphen;

4-5-dihydro-5-phenyl-2-oxazolamine) and its

salts, optical isomers, and salts of optical isomers;

(4) Methcathinone (some other names:

2-methylamino-1-phenylpropan-1-one;

Ephedrone; 2-(methylamino)-propiophenone;

alpha-(methylamino)propiophenone; N-methylcathinone;

methycathinone; Monomethylpropion; UR 1431) and its

salts, optical isomers, and salts of optical isomers;

(5) Cathinone (some trade or other names:

2-aminopropiophenone; alpha-aminopropiophenone;

2-amino-1-phenyl-propanone; norephedrone);

(6) N,N-dimethylamphetamine (also known as:

N,N-alpha-trimethyl-benzeneethanamine;

N,N-alpha-trimethylphenethylamine);

(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

(8) 3,4-Methylenedioxypyrovalerone (MDPV).

(g) Temporary listing of substances subject to emergency

scheduling. Any material, compound, mixture, or preparation

that contains any quantity of the following substances:

(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide

(benzylfentanyl), its optical isomers, isomers, salts,

and salts of isomers;

(2) N-[1(2-thienyl)

methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),

its optical isomers, salts, and salts of isomers.

(h) Synthetic cathinones. Unless specifically excepted,

any chemical compound not including bupropion, structurally

derived from 2-aminopropan-1-one by substitution at the

1-position with either phenyl, naphthyl, or thiophene ring

systems, whether or not the compound is further modified in one

or more of the following ways:

(1) by substitution in the ring system to

any extent with alkyl, alkylenedioxy, alkoxy,

haloalkyl, hydroxyl, or halide substituents, whether

or not further substituted in the ring system

by one or more other univalent substituents.

Examples of this class include, but are not

limited to, 3,4-Methylenedioxycathinone

(bk-MDA);

(2) by substitution at the 3-position

with an acyclic alkyl substituent. Examples of

this class include, but are not limited to,

2-methylamino-1-phenylbutan-1-one

(buphedrone); or

(3) by substitution at the 2-amino nitrogen

atom with alkyl, dialkyl, benzyl, or methoxybenzyl

groups, or by inclusion of the 2-amino nitrogen atom

in a cyclic structure. Examples of this class include,

but are not limited to, Dimethylcathinone, Ethcathinone,

and a-Pyrrolidinopropiophenone (a-PPP).

(Source: P.A. 97-192, eff. 7-22-11; 97-193, eff. 1-1-12;

97-194, eff. 7-22-11; 97-334, eff. 1-1-12; 97-813, eff.

7-13-12; 97-872, eff. 7-31-12; 98-987, eff. 1-1-15.)

Sec (Regarding Manufacture or Delivery of Controlled Synthetic drugs). 401.

Except as authorized by this Act, it is unlawful

for any person knowingly to manufacture or deliver, or possess

with intent to manufacture or deliver, a controlled substance

other than methamphetamine, a counterfeit substance, or a

controlled substance analog. A violation of this Act with

respect to each of the controlled substances listed herein

constitutes a single and separate violation of this Act. For

purposes of this Section, “controlled substance analog” or

“analog” means a substance which is intended for human

consumption, other than a controlled substance, that has a

chemical structure substantially similar to that of a

controlled substance in Schedule I or II, or that was

specifically designed to produce an effect substantially

similar to that of a controlled substance in Schedule I or II.

Examples of chemical classes in which controlled substance

analogs are found include, but are not limited to, the

following: phenethylamines, N-substituted piperidines,

morphinans, ecgonines, quinazolinones, substituted indoles,

and arylcycloalkylamines. For purposes of this Act, a

controlled substance analog shall be treated in the same manner

as the controlled substance to which it is substantially

similar.

Sec. 402 (Regarding Possession of Controlled Synthetic Drugs).

Except as otherwise authorized by this Act, it is

unlawful for any person knowingly to possess a controlled or

counterfeit substance or controlled substance analog. A

violation of this Act with respect to each of the controlled

substances listed herein constitutes a single and separate

violation of this Act. For purposes of this Section,

“controlled substance analog” or “analog” means a substance

which is intended for human consumption, other than a

controlled substance, that has a chemical structure

substantially similar to that of a controlled substance in

Schedule I or II, or that was specifically designed to produce

an effect substantially similar to that of a controlled

substance in Schedule I or II. Examples of chemical classes in

which controlled substance analogs are found include, but are

not limited to, the following: phenethylamines, N-substituted

piperidines, morphinans, ecgonines, quinazolinones,

substituted indoles, and arylcycloalkylamines. For purposes of

this Act, a controlled substance analog shall be treated in the

same manner as the controlled substance to which it is

substantially similar.

Section 5. Severability clause.

Section 6. Repealer clause.

Section 7. {Insert Effective Date}